Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe: full analysis
Bausch + Lomb has launched its Bi-Blade+ dual-port vitrectomy cutter in Europe on the Stellaris Elite Vision Enhancement System, extending a retinal surgery technology update that the company first took through the U.S. FDA in April 2026. In the company’s description, the new cutter is built to increase cut speed to 25,000 cuts per minute while maintaining the dual-port design and 100% open duty cycle that defined the earlier Bi-Blade platform. (streetinsider.com)
The launch builds on a longer Stellaris Elite strategy. Bausch + Lomb received CE Mark approval for the Stellaris Elite platform in Europe in 2018, positioning it as an upgradable cataract and vitreoretinal surgery system. That matters here because Bi-Blade+ is not a standalone launch; it’s another example of the company using the installed Stellaris Elite base to add new surgical capabilities over time. Adaptive Fluidics, the software update paired with Bi-Blade+ in the recent U.S. clearance, was previously introduced on the platform in 2024, according to the European launch coverage. (bauschsurgical.eu)
In the new European announcement, Bausch + Lomb said Bi-Blade+ delivers a 25% increase in average flow rate over the prior Bi-Blade model. The company also highlighted a 62% reduction in cutter vibration at maximum speed versus the original device. In the FDA-related materials, Bausch + Lomb tied those claims to bench, ex vivo, in vitro, and preclinical testing, and said the technology is intended to support more efficient vitreous removal, reduced retinal traction, and better stability when used with Adaptive Fluidics. (streetinsider.com)
Regulatory filings add a little more context. The FDA’s 510(k) summary for K252052, dated March 25, 2026, describes the Bi-Blade+ as substantially equivalent to the earlier Bi-Blade cutter under the same ophthalmic surgery regulation. The filing also confirms the labeled indications span anterior vitrectomy in anterior segment surgery as well as vitreoretinal conditions requiring posterior or combined surgery. That suggests the product story here is less about a brand-new category and more about an iterative performance upgrade within an established surgical workflow. (accessdata.fda.gov)
Bausch + Lomb also pointed to an outside surgeon perspective in its launch materials. Professor Marco Mura of the University of Ferrara said the higher cut rate offers an advantage in vitreous removal and that increasing flow while maintaining a small sphere of influence could give surgeons more confidence when working close to the retina. I didn’t find independent third-party reaction beyond pickup coverage of the company release, so that quote should be read as company-supplied commentary rather than a broad consensus view. (streetinsider.com)
Why it matters: For veterinary professionals, this is adjacent-market intelligence rather than a direct clinical development. Still, human ophthalmic device launches often signal where microsurgical engineering is heading: faster cutters, more stable fluidics, less vibration, and tighter control of intraocular pressure under demanding conditions. Those are relevant themes for specialists, referral hospitals, and industry teams watching how precision eye surgery platforms may evolve, even if this specific launch is aimed at human retinal surgeons in Europe. (streetinsider.com)
There’s also a business angle. Bausch + Lomb is using Europe as an early commercialization market for this iteration while building on recent U.S. regulatory momentum. That pattern can matter for competitors and suppliers because it shows how manufacturers are trying to extend platform value through accessories, software, and procedural refinements rather than relying only on entirely new capital systems. (streetinsider.com)
What to watch: The next things to watch are whether Bausch + Lomb publishes more clinical performance data beyond bench and preclinical findings, how quickly surgeons adopt the upgrade on existing Stellaris Elite systems, and whether additional market launches or reimbursement-related messaging follow later in 2026. (streetinsider.com)